BSG BioNewsletter *Antifungals*Swedish Biopharma* 05#2002

Anna Johansson anna.johansson at
Tue Oct 8 18:16:00 EST 2002

BSG BioNewsLetter 05#2002 - BioSeeker Group's analysis and products eNewsletter



1) Swedish Biopharma at Large - What Next?
2) New Report: 'The Next Generation Antifungals: Triazoles vs. Peptides'
3) Recently published BioSeeker Reports
4) Swedish Biotech Packages
5) Seek And You Will Find
6) Conference Opportunity - Ion Channels in Drug Discovery & Development
7) Coming reports: HCV Therapy / Winning the Osteoporosis Therapy Race
8) Subscription
9) BioSeeker Online Store



The Swedish biopharma industry has more than doubled in the last six years, growing from 25 companies in 1996 to the current 52. Next to the medical device industry the biopharma industry is the largest biotech industry segment in Sweden. The predominant disease groups for R&D in Swedish biopharma are: Inflammation / autoimmune, metabolic, cancer, infectious, and neurological diseases. However, the pipeline of the industry is in its infancy. 

Read the full version of this free, analytical BioNewsletter article at


   - A New Report from BioSeeker Group

According to the Antifungal Work Group at NIH there is a "critical need for the development of antifungal agents". There will be tight competition for market shares when PfizerÕs patent on fluconazole (the active ingredient in Diflucan(TM)) expires in 2004. Both Bristol-Myers Squibb and Schering-Plough will try to compete for market shares. In this Highlight Report, we present new data on activites in the field of triazole and peptide antifungals. Topics considered in this report are :

- Research (spectrums, activities, side-effects, resistance and drug interactions) 
- Patents
- Clinical trials (indications, status and activities)
- Partnerships
- Expected market launches and sales

For more information about this report, please visit



- Swedish Biopharma Industry - The Next Wave (released Sept, 2002)

- Ion Channel Assays in the Drug Discovery Process (released June, 2002)

- The Competitive Landscape of Cancer Gene Therapy (released May, 2002)

- Commercializing on Tumor Antigens: Analytical Perspectives (released Feb, 2002)



a) Order the new report 'Swedish Biopharma Industry' together with the report 'Swedish Biotechnology Industry' (published Jan. 2001) for $1050 (save $200).

b) Obtain five free company profiles from the Swedish Biotech Corporate Index with any purchase of 'Swedish Biopharma Industry' (price $850 US).

c) Order 'Swedish Biotechnology Industry' together with the address list 'Complete Contact Data to Swedish Biotechnology Companies', updated continously and containing contact details to more than 320 Swedish Biotech companies, for $699 (save $350).

When ordering one of these packages, please place your order by fax and use reference codes SWEPACK-A, B or C. (Download orderform at



Identify and locate your potential customers, competitors, and partners by using BioSeeker Group's world-wide company search service. This service is based on BioSeeker's in-house company database built up during four years of operation and containing more than 10,000 life science companies globally.

We offer you this service in 3 steps:

Step 1. Search & Identify (399 USD)

Step 2. Locate & Validate (699 USD)

Step 3. Select & Build (individual price). Choose the companies of interest and BSG builds extensive profiles of those.

For more information about this service, please contact us at bioinfo at



- Ion Channels in Drug Discovery & Development, Oct. 24-25, 2002, Princeton, NJ

The 2nd International Ion Channels in Drug Discovery & Development meeting will feature a new focus on drug discovery applications.  Presentations will cover drug discovery efforts, automated electrophysiology advances, and clinical development of ion channel compounds.  Network with scientists from big pharma, biotech, and academia in this exciting and emerging research area.  Hear from companies including: Abbott Laboratories, Amersham Biosciences, AstraZeneca, Evotec OAI, Icagen, Merck Research Laboratories, NeuroMed Technologies, NeuroSearch, Schering-Plough Research Institute, Zyomyx, National Cancer Institute, New York University School of Medicine, University of California at Irvine, University of California at San Diego, University of Florida at Gainesville, Weill Medical College of Cornell University.  To register, phone 888-666-8514 (toll-free) or 646-336-7030 or register online at  Mention Priority Code DEM002261 when registering.



- Molecular Approaches Towards New HCV Therapy

Treatment of HCV (Hepatitis C Virus) is a market with unmet medical needs, with relatively young people infected and a high risk for chronic disease. The coming decade will see exciting developments in HCV therapy thanks to breakthroughs in overcoming a major barrier to development: the lack of dedicated models suitable for validating candidate compounds in a low-cost, highthroughput format. BioSeeker Group has identified at least 115 companies with interest in various stages in the field of HCV therapy. Out of these 100, approximately 10 of the 'big pharma' are represented. Our coming report "Molecular Approaches Towards New HCV Therapy" analyses the field of new HCV therapeutics and assess possible outcomes for drugs and companies in this sector. 

Please contact us at bioinfo at for more information about this report.For further reading about HCV, please visit our free analytical article on this topic (

- Winning the Osteoporosis Therapy Race

Osteoporosis, deterioration of bone tissue and an increased risk of fractures, is considered by the World Health Organization to be second only to cardiovascular disease as a leading healthcare problem. According to other studies, sales of osteoporosis drugs in these markets totaled $3.4 billion in 2000, and are expected to reach $6.5 billion by 2005. A new class of osteoporosis therapies, designed to build bone mass in contrast to currently available anti-osteoporosis medicines are presently under study. These anabolic therapies consist of parathyroid hormone (FortÎoª and ALX-11) or fluoride to stimulate bone formation, but their safety and efficacy remain to be established. The first of these drugs to reach the market will probably be FortÎoª, known generically as teriparatide (recombinant parathyroid hormone).

Please contact us for more information about this report (bioinfo at For further reading about osteoporosis, please visit our free analytical article on this topic (



To continue to stay tuned with coming editions of BioSeeker Groups BioNewsLetter, please send an email to subscribe at



BioSeeker has now made it easy to order any of our products online, directly from our website. Visit  to place an online order.


Do you have a message that you would like the biotech community to know? BioSeeker Group's Newsletter targets managers, scientists, venture capitalists, consultants and many more world wide. Contact us at sales at for further information on how to advertise in BSG BioNewsletter.


If you would like to comment on our newsletter please send us an email to feedback at

If you would like to be removed from our newsletter list, please reply to unsubscribe at



More information about the Cellbiol mailing list